Estrella Immunopharma, Inc.

The momentum for this stock is not very good. Estrella Immunopharma, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Estrella Immunopharma, Inc..

News

Estrella Immunopharma names Hong Zhang as chairperson

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Business Wire Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ('Estrella', Estrella Immunopharma, or the 'Company'), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted...\n more…

Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Ticker Report Estrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 17,600...\n more…

Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Increase in Short Interest

Zolmax Estrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) saw a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 10,900 shares, an...\n more…

Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Ticker Report Estrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) saw a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 10,900 shares, an...\n more…

ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nEstrella Immunopharma just reported results for the third quarter of 2024.\nThe post ESLA Stock Earnings: Estrella Immunopharma Reported...\n more…